Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial.
Ian E KropNorikazu MasudaToru MukoharaShunji TakahashiTakahiro NakayamaKenichi InoueHiroji IwataYutaka YamamotoRicardo H AlvarezTatsuya ToyamaMasato TakahashiAkihiko OsakiShigehira SajiYasuaki SagaraJoyce O'ShaughnessyShoichi OhwadaKumiko KoyamaTatsuya InoueLi LiParul PatelJoseph MostilloYoshimi TanakaDavid W SternbergDalila SellamiKan YonemoriPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
HER3-DXd demonstrated a manageable safety profile and durable efficacy in heavily pretreated patients across clinical subtypes. These data warrant further evaluation of HER3-DXd in patients with HER3-expressing metastatic breast cancer.
Keyphrases
- epidermal growth factor receptor
- metastatic breast cancer
- tyrosine kinase
- advanced non small cell lung cancer
- endothelial cells
- newly diagnosed
- end stage renal disease
- induced pluripotent stem cells
- ejection fraction
- electronic health record
- study protocol
- machine learning
- cancer therapy
- big data
- phase iii
- placebo controlled
- wild type